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Abstract
Objective. To assess if HIV-infected women made different choices for postpartum sterilization after implementation of the
Pediatric AIDS Clinical Trials Group protocol 076 (November 1, 1994) compared to before implementation.
Study design. A retrospective cohort study in which medical records were reviewed to obtain demographic, obstetric and
HIV-related data from January 1993 through December 2002. HIV-infected women who completed a pregnancy by birth or
abortion were divided into two comparison groups: ‘‘Pre-076’’ and ‘‘Post-076’’. The primary outcome was sterilization by
postpartum tubal ligation.
Results. Forty-two women (74%) in the Pre-076 group chose sterilization compared to 139 of 310 women (45%) in the
Post-076 group (unadjusted OR 3.44, 95% CI 1.83, 6.47). Seventy-one percent of women younger than 21 years of age in
the Pre-076 Group chose sterilization compared with only 35% of women younger than 21 years in the Post-076 group
(p=0.0136). Similarly, 78% of primiparous women chose sterilization after their ﬁrst pregnancy in the Pre-076 group,
compared to 14% in the Post-076 group (p50.001).
Conclusions. Since the implementation of PACTG 076 protocol in November 1994, fewer HIV-infected women chose
postpartum sterilization. The typical woman who now chooses postpartum sterilization is less likely to be young or
primiparous than those who chose sterilization before PACTG Protocol 076 implementation.
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Introduction
Over 85,000 women of reproductive age (15–44
years) in the United States are infected with the
human immunodeﬁciency virus (HIV) [l]. Anti-
retroviral therapy and advances in management of
HIV disease have decreased the maternal-infant
vertical transmission rate of HIV from 25% to less
than 2% [2–4], and have changed HIV infection from
a life-threatening illness to a chronic disease [5,6].
Previous studies have evaluated the impact that
knowledge of HIV seropositivity has on the repro-
ductive health decisions made by women [7–10], and
HIV-infected women have been reported to be more
likely to choose sterilization than women who are not
infected [11,12]. In November 1994 the results of the
Pediatric AIDS Clinical Trial Group (PACTG)
Protocol 076 were published which indicated that
antepartum, intrapartum, and neonatal administra-
tion of zidovudine could decrease the vertical
transmission rate of HIV from 25% to 8% [3]. Our
study objective was to determine if the postpartum
sterilization rate in HIV-infected women changed
after implementation of PACTG Protocol 076. A
secondary objective was to determine any overall
changes in choice of postpartum contraceptive
method over the same time period in this population.
Materials and methods
This was a time-series cohort study at Parkland
Memorial Hospital (PMH) from January 1, 1993
through December 31, 2002. PMH is the tertiary
care hospital of the Parkland Health and Hospital
System which serves Dallas County. PMH has a busy
obstetrics service with over 16,000 deliveries a year.
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pregnancy are staffed by attending physician faculty.
All HIV-infected pregnant women are followed in
one multidisciplinary infectious disease obstetrics
clinic, where patients are seen by resident physicians
and mid-level health care providers. The annual
number of HIV-infected pregnant women managed
per year at PMH has ranged from around 40 to 81
during the years studied.
HIV-infected pregnant women are counseled at
their ﬁrst prenatal visit by Maternal Fetal Medicine
attendings and one registered nurse. For subsequent
visits written protocols are followed when appro-
priate, and overall supervision is provided by the
same faculty physicians who attend the clinic each
week. These faculty members coordinate care with
Internal Medicine Infectious Disease specialists as
necessary. Future plans for birth control are dis-
cussed with patients during their prenatal visits and
again when they return for their postpartum visits.
Women are counseled in a non-judgmental manner,
by the provider seeing them for the visit, regarding all
contraceptive methods available to them, including
the risks and beneﬁts of each method as known at the
time. Postpartum sterilization by bilateral tubal
ligation (BTL) is one of the options included in
those discussions; that option has never been the sole
recommendation. The only contraceptive method
that has always been recommended is use of
condoms.
We included HIV-infected pregnant women who
completed a pregnancy during the study period at
PMH and whose complete medical records were
available in the study cohort. We divided the
complete cohort into a ‘‘Pre-076 Group’’ and a
‘‘Post-076 Group’’ for comparison. The Pre-076
Group comprised HIV-infected pregnant women
who did not receive PACTG Protocol 076 counsel-
ing because their date of presentation was before
November 1994. This counseling included the
information that use of zidovudine (ZDV) during
the antepartum, intrapartum and neonatal period
could decrease the risk of HIV transmission to their
infant from 25% to 8%. The Post-076 Group
comprised women who presented after November
1994, or who presented at an early enough gesta-
tional age (prior to 14 weeks) to initiate antiretroviral
treatment in November 1994. For those HIV-
infected women who completed more than one
pregnancy at PMH during the study time period
only the decision and pregnancy outcome of the
lattermost pregnancy was included in the data
analysis. Women were excluded if they had incom-
plete medical records or pregnancy outcomes we felt
would signiﬁcantly alter sterilization decisions such
as fetal demise or fetal death. Maternal death and
abortion-hysterectomies were also excluded.
We reviewed medical records and abstracted data
for demographic characteristics, delivery or abortion
information, AIDS diagnosis according to the
Centers for Disease Control (CDC) deﬁnition [13],
prenatal care attendance, and the choice for post-
partum sterilization or other contraceptive method.
This was a retrospective chart review of HIV-infected
women’s choices of postpartum BTL at PMH. We
reviewed all data available to us, and therefore no
power analysis was done.
Statistical analyses included Pearson Chi-square,
and Student’s t-test for comparison of means.
Welch’s approximation was applied when necessary
to account for unequal variances. The Wilcoxon
rank-sum test was used for non-parametric analysis.
P-values less than 0.05 were statistically signiﬁcant.
This research was exempted from full review by the
Institutional Review Board of the University of Texas
Southwestern Medical Center.
Results
From January 11993 through December 312002,
426 HIV-infected women completed at least one
pregnancy at Parkland Memorial Hospital. We
excluded a total of 59 women; 52 women with
incomplete medical records, and seven women with
adverse pregnancy outcomes which included 2
women who had fetal demises, one maternal death,
three abortion-hysterectomies and one termination
for a fetal anomaly. The ﬁnal cohort consisted of 367
women (86%). For the seventy-eight women who
completed more than one pregnancy we analyzed
only the lattermost pregnancy and the decision made
at that pregnancy.
The Pre-076 Group comprised HIV-infected preg-
nant women who did not receive PACTG Protocol
076 counseling because their date of presentation was
before November 1994, the date the manuscript
reporting the results of the PACTG 076 study was
published [3]. It is likely that results of PACTG 076
were preliminarily available prior to publication and
therefore some women prior to this date may have
received more extensive counseling regarding the
beneﬁts of the triple therapy protocol using ante-
partum, intrapartum and neonatal zidovudine
administration. The decision to choose November
1993, the date of publication of 076, was made
because it was an identiﬁable date. Additionally, with
publication comes validation of the results and there-
fore, acceptance by patients. While this date choice
may have been speculative, it was a date which could
be pointed to at which counseling would have
deﬁnitely changed.
Using those criteria, 57 women made up the Pre-
076 group. The Post-076 Group comprised women
who presented after November 1994, or who
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14 weeks) to initiate anti-retroviral treatment in
November 1994. The Post-076 group included 310
women.
The mean age did not differ between the two
groups (Table I). There was also no difference in
race, with the majority of women being African-
American, followed by Hispanic and Caucasian.
Five percent of the Post-076 group versus 9% of the
Pre-076 group had an HIV-infected child prior to
the pregnancy evaluated for the study. While there
is not a statistically signiﬁcant difference between
these, the rate of having a previous child infected
with HIV was almost doubled in the Post-076
cohort. The majority of women in both groups
received prenatal care. The mode of delivery and
the abortion rate in both groups were similar.
Twenty-eight percent of women in the Pre-076
group had cesarean delivery compared to 33% in
the Post-076 group A similar proportion of women
in both groups had received a diagnosis of AIDS
according to the CDC criteria [13].
Figure 1 summarizes the study cohort and the
sterilization choices of the HIV-infected women. Of
the ﬁfty-seven women in the Pre-076 group forty-two
(74%) chose postpartum sterilization for their
method of contraception after completion of their
lattermost pregnancy at PMH, compared to only 15
of the 57 (26%) choosing to maintain their fertility.
In the Post-076 Group, less than half of the women
(139 of 310, 45%) chose sterilization as their method
of contraception after pregnancy completion, com-
pared to 171 of 310 (55%) choosing to maintain
fertility. This difference between the Pre-076 group
and the Post-076 group was statistically signiﬁcant
with p50.001.
We analyzed subgroups to evaluate if age or parity
affects sterilization decisions. We divided age into
three categories for comparison: women under the
age of 21 years, women ages 21–34 years, and
Table I. Selected demographics.
Pre-076 Post-076
n=57 n=310 p-value
Age, yrs (mean+SD) 25.9+9.0 26.1+5.7 NS
Race NS
Black 40 (70%) 213 (69%)
Hispanic 9 (16%) 56 (18%)
White 7 (12%) 39 (13%)
Other 1 (2%) 1 (51%)
Type of Delivery NS
Vaginal Delivery 34 (60%) 171 (55%)
Cesarean Delivery 16 (28%) 102 (33%)
Abortion 7 (12%) 37 (12%)
Prior HIV-Infected Child 5 (9%) 14 (5%) NS
Date of HIV Diagnosis NS
Pre-Pregnancy 26 (46%) 171 (55%)
1–42 Weeks Gestation 30 (53%) 123 (40%)
Postpartum 1 (2%) 16 (5%)
Diagnosed with AIDS 9 (16%) 57 (19%) NS
Received Prenatal Care 52 (91%) 295 (95%) NS
Using Chi-sqare and Student’s t-test, p50.05 is signiﬁcant. NS, not signiﬁcant
Figure 1. Sterilization choices of HIV-infected women who completed their last pregnancy at Parkland Memorial Hospital 1 January, 1993 –
31 December, 2002.
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younger than 21 in the Pre-076 Group, ten out of 14
(71%) chose BTL, compared to 20 out of the 37
(35%) women younger than 21 years in the Post-076
Group; this difference was signiﬁcant with a p-value
of 0.014. Women between the ages of 21–34 also
showed a signiﬁcant decrease in their choice of
sterilization with 28 of 39 (72%) in the Pre-076
Group choosing sterilization compared to 101 of 225
(45%) in the Post-076 Group, p=0.002. There was
no signiﬁcant difference between women older than
34 years in the two groups.
We divided parity into four groups to assess if
parity had an effect on sterilization decisions: women
who had one child, two children, three children, or
more than three children (Table III). In the Pre-076
Group seven out of nine (78%) primiparous women
chose sterilization as their contraceptive method
compared to 10 of 74 (14%) in the Post-076 Group,
p50.001. A statistically signiﬁcant difference was
also seen among women who had delivered three
babies; 16 of 18 (88%) of these women chose
sterilization in the Pre-076 Group compared to only
39 of 66 (59%) in the Post-076 Group p=0.018.
Logistic regression was done to evaluate how
choices for sterilization may have changed over time.
We evaluated the probability of BTL by delivery
date. This demonstrated a signiﬁcant decrease over
time in women choosing BTL, p=0.002. The choice
for contraceptive method other than BTL was
abstracted from the medical records and was there-
fore not available for every study subject. Over time,
choice for condom use increased from 1% to 6% and
choice for medroxyprogesterone-acetate increased
from 2% to 12% (p50.0001).
Comment
Our study indicates that signiﬁcantly fewer HIV-
infected women chose postpartum sterilization after
it was known that medical intervention with zidovu-
dine during pregnancy and the immediate postpartum
period would decrease HIV vertical transmission.
Seventy-four percent of HIV-infected women chose
BTL prior to routine PACTG 076 implementation
at our institution compared to only 45% in the Post-
076 Group. Additionally, over time, the probability
of a woman choosing sterilization as her method of
contraception signiﬁcantly decreased. When age and
parity were evaluated, fewer younger women and
fewer primiparous women chose sterilization in more
recent years.
With the advent of PACTG 076, regular use of
triple antiviral therapy, and subsequent regular use of
highly-active antiretroviral therapy (HAART) and
cesarean delivery, the rate of maternal to child
transmission has continued to decline. Throughout
the era of HIV, pregnant women infected with HIV
Table II. The association of age with women who chose postpartum bilateral tubal ligation in the Pre-076 and Post-076 Groups.
Pre-076 Post-076
Chose BTL Chose fertility Chose BTL Chose fertility
Age (years) N=42 N=15 N=139 N=171 p-value
0.0001
21 10 (71%) 4 (29%) 20 (35%) 37 (35%) 0.0136
21–34 28 (72%) 11 (28%) 101 (45%) 124 (55%) 0.0019
434 4 (100%) 0 18 (64%) 10 (36%) NS
Using Chi-sqare and Student’s t-test, p50.05 is signiﬁcant. NS, not signiﬁcant. *=total number of women of each age in each cohort.
21 (N=14,57); 21–34 (N=39,225); 4 34 (N=4,28).
Table III. The association of parity and age with women who chose postpartum bilateral tubal ligation (PPBTL) in the Pre-076 compared to
Post-076 Groups.
Pre-076 Post-076
Chose BTL Chose Fertility Chose BTL Chose Fertility
Parity* N=42 N=15 N=139 N=171 p-value
0.0001
1 7 (78%) 2 (22%) 10 (14%) 64 (86%) 50.001
2 12 (57%) 9 (43%) 58 (48%) 63 (52%) NS
3 16 (88%) 2 (12%) 39 (59%) 27 (41%) 0.0184
43 7 (78%) 2 (12%) 32 (65%) 17 (35%) NS
Using Chi-sqare and Student’s t-test, p50.05 is signiﬁcant. NS, not signiﬁcant. *=total number of women of each parity in each cohort.
1( N=9,74); 2 (N=21,121); 3 (N=18,66); 43( N=9,49).
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primarily by the same clinicians (G.W., J.S. and
B.M.). HIV-infected women receive updated infor-
mation regarding rates of HIV transmission risk and
status of their own HIV disease throughout the
counseling.
The choice for contraceptive method overall also
changed signiﬁcantly over time (p50.0001). This is
attributable to the increase in condom use from 1%
to 6% and the increase in Depo-Provera
1 from 2%
to 12% in the Pre-076 Group compared to the Post-
076 Group. It is notable that in both groups the
contraceptive method most commonly chosen was
BTL. A high proportion of HIV-infected women
in our cohort underwent postpartum sterilization
despite non-judgmental and non-directional coun-
seling. We suspect this was due to the poor prognosis
of HIV disease at the time. We could ﬁnd no law in
the state of Texas prohibiting sterilization of women
below a certain age, nor a law requiring a certain
amount of patient contact prior to the procedure.
Our ﬁndings are consistent with other published
studies. Investigators from Brazil found that knowl-
edge of HIV seropositive status increased the
prevalence of bilateral tubal ligation [12]. A study
on the impact of the knowledge of HIV serostatus and
contraceptive choice and repeat pregnancy found
that seropositive women were less likely to have a
subsequent pregnancy and more likely to choose
sterilization [11]. This is in contrast to a cohort of
Midwestern non-injecting drug use women in whom
knowledge of HIV infection and the use of zidovudine
to decrease vertical transmission was not associated
with a change in abortion consideration or pregnancy
planning [9]. A survey of 1,421 HIV-infected men
and women [14] found that 69% of reproductive age
HIV-infected women in the United States desire to
have children in the future. We believe our ﬁnding
that fewer young, nulliparous women are choosing
BTL is due to the decreasing vertical transmission
rates associated with the use of effective antiretroviral
therapy. The status of HIV disease is one factor of
many, including sociocultural and behavioral beliefs,
which can impact reproductive decision making [15].
As indicated by our demographic data the basic
demographics of our population were not different
between the two groups; therefore, we believe the
decrease in sterilization is largely due to the decrease
in the rate of maternal to child transmission of HIV.
Our study supports the argument that as HIV
infection continues to change to a chronic asympto-
matic disease HIV-infected women can look for a
brighter future with more childbearing plans than
they had in the past.
In this study postpartum sterilization has been used
as a surrogate for measurement of fertility wishes in
HIV-infected women. This can be misleading both
because adequate reversible contraceptive options are
available and because fertility in HIV-infected women
can be affected by anovulation and infertility as a
result of HIV-related illnesses [16]. Also, it is possible
that some women who chose not to have a tubal
ligation at PMH may have gone to another hospital
for a subsequent pregnancy where they may have
decided to have a tubal ligation. We believe that most
HIV-infected women cared for at PMH chose to
return to PMH for their subsequent pregnancy-
related care, as evidenced by the 78 women who
had multiple pregnancies at PMH. Thus, loss to
follow up is likely minimal. Abortions were not
separated and analyzed differently because the cohort
was small and we felt analysis of this subgroup would
not add anything to the study.
There are changes over time which can affect a
before and after study design such as this one.
Speciﬁcally, there were changes in mandatory HIV
testing of pregnant women during the study period
which could affect HIV disease ascertainment. In
1996 it became mandatory for all pregnant women in
the state of Texas to be offered HIV testing when
they presented for initiation of prenatal care, and at
time of labor and delivery [17]. It is therefore
possible all HIV-infected pregnant women were not
detected at PMH prior to 1996, although pregnant
women who were considered to be high risk, due to a
history of previous sexually transmitted infections or
drug use, were counseled and offered HIV testing at
our institution before mandatory testing was im-
plemented in Texas.
With the use of cesarean delivery and additional
anti-retroviral medications, a further reduction in the
vertical transmission rate to less than 2% [2] has
contributed to an even further decline than the initial
decline in transmission rate from 28% to 8% after
PACTG Protocol 076 was initiated. As life expec-
tancy and disease manifestation of HIV-infection
continues to improve due to continued advances in
disease management, it is reasonable to expect that
more HIV-infected women will want to maintain
their options for future fertility. As shown in this
report, fewer HIV-infected women are choosing
sterilization and more HIV-infected women are
choosing reversible methods of contraception. Our
conclusions support the need for continuing research
to address the special reproductive needs of HIV-
infected women as we continue in the era of HIV as a
chronic infection.
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